ArticleScientific reports2026
Downregulated m⁵C regulator NSUN6 enhances proliferation, migration and affects immune regulation in ovarian cancer.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Ovarian cancer (OC) remains one of the most lethal gynecological malignancies, largely due to late diagnosis and high metastatic potential. RNA 5-methylcytosine (m⁵C) modification has emerged as a key regulatory mechanism in cancer biology, yet the role of m⁵C-related genes such as NSUN6 in OC remains poorly understood. In this study, we first obtained three OC datasets and one m5C-related dataset from the GEO database and identified differentially expressed genes (co-DEGs) using Venn diagram analysis. Kaplan Meier plotter showed that NSUN6 was the only regulator significantly associated with patient prognosis. Additionly, Western Blot, Online database analysis and immunohistochemical staining evaluation showed that NSUN6 was significantly downregulated in OC and negatively correlated with tumor stage, metastasis and survival. Next, we overexpressed NSUN6 in OC cell lines. CCK8, wound healing and Transwell assays demonstrated that NSUN6 overexpression inhibited OC cell proliferation, migration, and invasion. Rescue experiments confirmed NSUN6-mediated suppression of AKT phosphorylation. In vivo xenograft models confirmed the tumor-suppressive effect of NSUN6, showing reduced tumor burden in both intraperitoneal and subcutaneous models. Bioinformatic analyses revealed enrichment in immune-related pathways and correlations with immune infiltration markers, which were further validated using ovarian cancer clinical samples. Collectively, our results demonstrate that NSUN6 is downregulated in OC and suppresses OC proliferation, migration, and invasion by inhibiting AKT activity, highlighting its potential as a therapeutic target in OC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.